Observations on the effect of ethyl a-p chlorophenoxyisobutyrate (CPIB) therapy on serum lipid levels and on diabetic and some other retinopathies.
D000328:Adult; D000368:Aged; D000738:Androsterone / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D002087:Butyrates / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D003930:Diabetic Retinopathy / Q000188:drug therapy*; D005128:Eye Diseases / Q000188:drug therapy; D005260:Female; D005654:Fundus Oculi; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008055:Lipids / Q000037:antagonists & inhibitors*; D008297:Male; D008875:Middle Aged; D012160:Retina; D014280:Triglycerides / Q000097:blood*
D000924:Anticholesteremic Agents; D002087:Butyrates; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D002784:Cholesterol; D000738:Androsterone